REYKJAVIK, Iceland, July 18 /PRNewswire-FirstCall/ -- deCODE genetics today announced that it has named Earl M. “Duke” Collier, Jr to its Board of Directors, effective immediately. Mr. Collier is an Executive Vice President at Genzyme Corp. He has previously served as President of Vitas Healthcare, was a partner at the Washington, DC-based law firm of Hogan and Hartson, and served as Deputy Administrator of the Health Care Finance Administration (now CMS) in the Department of Health and Human Services. Mr. Collier received his BA from Yale University and his JD from the University of Virginia.
“Duke has had hands-on experience in virtually every aspect of healthcare, from product development to licensing, healthcare delivery, and reimbursement. He has maintained an association with Genzyme for over 15 of its 25 year history, for the last decade as an executive officer. His participation in Genzyme’s growth and development during those years, together with his other experiences, will make him a very valuable member of our team as we advance our own products towards the market,” said Kari Stefansson, CEO of deCODE.
About deCODE
deCODE genetics is a global leader in applying human genetics to develop drugs for common diseases. Our population approach has enabled us to discover and target key biological pathways involved in conditions ranging from heart attack to cancer. We are turning these discoveries into new medicine to better treat and prevent many of the biggest challenges to public health. deCODE is delivering on the promise of the new genetics.SM Visit us on the web at www.decode.com.
Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to technology and product development, integration of acquired businesses, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks identified in deCODE’s filings with the Securities and Exchange Commission. deCODE undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.
deCODE genetics
CONTACT: Contact: deCODE genetics, Eirikur Sigurdsson, +354-570-1993,info@decode.is. Joy Bessenger, +1-212-481-3891, ir@decode.is
